The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Roche Tenderly Completes Genentech Deal

The results are in: 84.7% of Genentech’s publicly held shares were tendered and will be taken up by Roche Investments USA Inc. for $95 per share, bringing Roche’s stake up to 93.2% (96.2% with the guaranteed deliveries).  Just a short form merger away from done.

Next challenge: integration without assimilation.

Bookmark and Share

About these ads

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 129 other followers